These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 24982342)

  • 1. Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.
    Schreiber V; Kitzmueller M; Poxhofer M; Gintersdorfer S; Neudorfer C; Lichtneckert M; Dittrich C; Czejka M
    Anticancer Res; 2014 Jul; 34(7):3371-6. PubMed ID: 24982342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.
    Farkouh A; Ettlinger D; Schueller J; Georgopoulos A; Scheithauer W; Czejka M
    Anticancer Res; 2010 Dec; 30(12):5207-11. PubMed ID: 21187514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
    Farkouh A; Scheithauer W; Buchner P; Georgopoulos A; Schueller J; Gruenberger B; Czejka M
    Anticancer Res; 2014 Jul; 34(7):3669-73. PubMed ID: 24982385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
    Sekido M; Fujita KI; Kubota Y; Ishida H; Takahashi T; Ohkuma R; Tsunoda T; Ishikawa F; Shibanuma M; Sasaki Y
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1127-1135. PubMed ID: 30972456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens.
    Farkouh A; Schueller J; Scheithauer W; Czejka M
    Int J Clin Pharmacol Ther; 2010 Jul; 48(7):487-8. PubMed ID: 20557855
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics and metabolism of irinotecan combined with capecitabine in patients with advanced colorectal cancer.
    Czejka M; Schueller J; Hauer K; Ostermann E
    Anticancer Res; 2005; 25(4):2985-90. PubMed ID: 16080556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
    Czejka M; Schueller J; Farkouh A; Gruenberger B; Scheithauer W
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):613-9. PubMed ID: 20495919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
    Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
    Urien S; Rezaí K; Lokiec F
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):817-33. PubMed ID: 16284918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
    Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
    Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral capecitabine (Xeloda) in cancer treatment.
    Doyle DP; Engelking C
    Nurse Pract; 2007 Feb; 32(2):18-21. PubMed ID: 17264789
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer.
    Satoh T; Omuro Y; Sasaki Y; Hamamoto Y; Boku N; Tamura T; Ohtsu A
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):949-55. PubMed ID: 22116464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
    Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
    J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
    Vainchtein LD; Rosing H; Schellens JH; Beijnen JH
    Biomed Chromatogr; 2010 Apr; 24(4):374-86. PubMed ID: 19650151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
    Cai X; Fang JM; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
    Eur Rev Med Pharmacol Sci; 2014; 18(8):1247-58. PubMed ID: 24817302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.
    Deenen MJ; Rosing H; Hillebrand MJ; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jan; 913-914():30-40. PubMed ID: 23270936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
    Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
    Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030).
    Louie SG; Ely B; Lenz HJ; Albain KS; Gotay C; Coleman D; Raghavan D; Shields AF; Gold PJ; Blanke CD
    Br J Cancer; 2013 Oct; 109(7):1744-9. PubMed ID: 24022189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography.
    Dhananjeyan MR; Liu J; Bykowski C; Trendel JA; Sarver JG; Ando H; Erhardt PW
    J Chromatogr A; 2007 Jan; 1138(1-2):101-8. PubMed ID: 17070825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.
    Besnard T; Renée N; Etienne-Grimaldi MC; François E; Milano G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(1):117-20. PubMed ID: 18562256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.